InflaMix Identifies CAR-T Recipients with a Preinfusion Inflammatory Profile Indicative of High Risk for CAR-T Treatment Failure By Ogkologos - May 5, 2025 373 0 Facebook Twitter Google+ Pinterest WhatsApp A valuable tool for point-of-care clinical decision-making in patients with non-Hodgkin lymphoma Source RELATED ARTICLESMORE FROM AUTHOR Treatment with Encorafenib Plus Cetuximab Plus FOLFIRI Improves Outcomes in Patients with BRAF V600E-mutated mCRC FDA Approves Belzutifan with Pembrolizumab for Adjuvant Treatment of Renal Cell Carcinoma How Decades of NCI Support Led to Groundbreaking Discoveries: The Story of Immune Checkpoint Inhibitors MOST POPULAR New on NCI’s Websites for December 2020 December 31, 2020 Evaluation of Primary and Secondary Prevention of Oral Cancer October 28, 2022 PDX Mouse Models Are Reliable Stand-Ins for Human Tumors, Study Finds February 2, 2021 Answers to Your Questions About the COVID-19 Vaccine March 4, 2021 Load more HOT NEWS Breastfeeding Patterns and Relation to Breast Cancer Outcomes After Early, Hormone... Skull Implant Delivers Drugs with Precision, Offering Hope for Parkinson’s, Cancer,... Cincinnati Police Are Wearing Pink Badges For Breast Cancer Awareness COVID-19 Is Decimating Nursing Homes, So GreaterGood Has Donated Masks To...
